for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novavax, Inc.

NVAX.OQ

Latest Trade

7.43USD

Change

0.34(+4.80%)

Volume

2,645,250

Today's Range

7.25

 - 

8.13

52 Week Range

3.54

 - 

48.60

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Novavax Files For Offering Of Up To $100 Mln Of Common Stock

Jan 21 (Reuters) - Novavax Inc <NVAX.O>::NOVAVAX INC FILES FOR OFFERING OF UP TO $100.0 MILLION OF COMMON STOCK - SEC FILING.

Novavax Posts Q3 Loss Per Share Of $0.74

Nov 7 (Reuters) - Novavax Inc <NVAX.O>::NOVAVAX REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.74.Q3 EARNINGS PER SHARE ESTIMATE $-0.98 -- REFINITIV IBES DATA.Q3 REVENUE $2.5 MILLION VERSUS REFINITIV IBES ESTIMATE OF $2.5 MILLION.AS OF SEPT 30, HAD $75.9 MILLION IN CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES & RESTRICTED CASH.

Novavax Inc - EMA Concluded That Co Would Not Be Able To Use Conditional Marketing Authorization Pathway For Resvax In EU

Sept 9 (Reuters) - Novavax Inc <NVAX.O>::NOVAVAX INC - EMA CONCLUDED THAT COMPANY WOULD NOT BE ABLE TO UTILIZE CONDITIONAL MARKETING AUTHORIZATION PATHWAY FOR RESVAX IN EUROPEAN UNION.

Novavax Q2 Loss Per Share $1.69

Aug 7 (Reuters) - Novavax Inc <NVAX.O>::NOVAVAX REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $1.69.Q2 EARNINGS PER SHARE ESTIMATE $-1.61 -- REFINITIV IBES DATA.Q2 REVENUE $3.4 MILLION VERSUS REFINITIV IBES ESTIMATE OF $3.1 MILLION.

Novavax Reaches Agreement With FDA On Late Stage Trial Design For Nanoflu

Aug 5 (Reuters) - Novavax Inc <NVAX.O>::NOVAVAX REACHES AGREEMENT WITH THE FDA ON PIVOTAL PHASE 3 TRIAL DESIGN FOR NANOFLU.NOVAVAX REACHES AGREEMENT WITH THE FDA ON PIVOTAL PHASE 3 TRIAL DESIGN FOR NANOFLU.NOVAVAX INC - CLINICAL TRIAL EXPECTED TO INITIATE IN FALL OF 2019.NOVAVAX INC - TOP-LINE CLINICAL DATA EXPECTED IN Q1 OF 2020.NOVAVAX INC - RECEIVED INPUT FROM U.S. FDA ON END-OF PHASE 2 QUESTIONS, REACHED AGREEMENT ON PHASE 3 TRIAL DESIGN FOR NANOFLU.

Novavax To Utilize Accelerated Approval Pathway For Licensure For Nanoflu

June 27 (Reuters) - Novavax Inc <NVAX.O>::NOVAVAX SAYS WILL UTILIZE ACCELERATED APPROVAL PATHWAY FOR LICENSURE FOR NANOFLU, ITS NANOPARTICLE SEASONAL INFLUENZA VACCINE CANDIDATE.NOVAVAX - EXPECTS TO INITIATE PIVOTAL PHASE 3 CLINICAL TRIAL FOR NANOFLU BY FALL OF 2019 WITH TOP-LINE CLINICAL DATA EXPECTED IN Q1 2020.NOVAVAX - WILL CONDUCT END-OF-PHASE 2 MEETING WITH FDA IN Q3 2019 TO DISCUSS PROPOSED PHASE 3 CLINICAL TRIAL DESIGN FOR NANOFLU.

Novavax Provides Updates On The Global Pathways To Licensure For Resvax

June 10 (Reuters) - Novavax Inc <NVAX.O>::NOVAVAX PROVIDES UPDATES ON THE GLOBAL PATHWAYS TO LICENSURE FOR RESVAX™.NOVAVAX INC - U.S. FOOD & DRUG ADMINISTRATION (FDA) HAS RECOMMENDED THAT NOVAVAX CONDUCT AN ADDITIONAL PHASE 3 CLINICAL TRIAL.NOVAVAX - PHASE 3 CLINICAL TRIAL TO CONFIRM EFFICACY AGAINST MEDICALLY SIGNIFICANT RSV DISEASE IN INFANTS BORN TO MOTHERS VACCINATED WITH RESVAX.NOVAVAX INC - BILL & MELINDA GATES FOUNDATION CONTINUES TO WORK WITH NOVAVAX ON A PATH TO INTRODUCE RESVAX TO LOW AND MIDDLE INCOME COUNTRIES.

Novavax Q1 Loss Per Share $0.11

May 2 (Reuters) - Novavax Inc <NVAX.O>::NOVAVAX REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.11.Q1 EARNINGS PER SHARE ESTIMATE $-0.11 -- REFINITIV IBES DATA.Q1 REVENUE $4.0 MILLION VERSUS REFINITIV IBES ESTIMATE OF $3.9 MILLION.NOVAVAX - AS OF MARCH 31, 2019, HAD $108.7 MILLION IN CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES & RESTRICTED CASH, VERSUS $103.9 MILLION AS OF DEC 31, 2018.

Novavax Reports Q1 Loss Per Share $0.11

May 2 (Reuters) - Novavax Inc <NVAX.O>::NOVAVAX REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.11.Q1 REVENUE $4.0 MILLION VERSUS REFINITIV IBES ESTIMATE OF $3.9 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.11 -- REFINITIV IBES DATA.

Novavax Q4 Loss Per Share $0.13

Novavax Inc <NVAX.O>::NOVAVAX REPORTS FOURTH QUARTER AND YEAR-END 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.13.Q4 EARNINGS PER SHARE ESTIMATE $-0.12 -- REFINITIV IBES DATA.Q4 REVENUE $6.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $7.1 MILLION.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up